Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Hofseth Biocare ASA ( (HOFBF) ) has issued an announcement.
Hofseth BioCare ASA has released a whitepaper highlighting the unique benefits of its bioactive peptide ingredient, ProGo®, which supports GLP-1 therapy by protecting lean muscle mass. ProGo® offers a complete amino acid profile, antioxidant properties, and inhibits muscle mass regulators, distinguishing it as a high-quality nutritional supplement with superior bioavailability. This development positions HBC as a leader in innovative health solutions, potentially impacting stakeholders by enhancing the company’s market presence and scientific credibility.
More about Hofseth Biocare ASA
Hofseth BioCare ASA is a Norwegian company focused on consumer and pet health, emphasizing sustainability and optimal resource utilization. The company transforms salmon industry by-products into health ingredients like ProGo®, OmeGo®, and CalGo®/NT-II®, which offer benefits such as improved iron metabolism, immune health, and bone and joint support.
Average Trading Volume: 100,957
Current Market Cap: NOK719.4M
Learn more about HOFBF stock on TipRanks’ Stock Analysis page.